Description

This is a single-center, prospective interventional translational study designed to identify and validate proteomic biomarkers in patients affected by age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinal detachment (RD), compared with control subjects without retinal disease.

Study Population

Approximately 260 subjects will be enrolled, including:

180 patients (100 AMD, 50 DR, 30 RD) 80 controls (cataract surgery or macular surgery patients without retinal disease) Participants will be recruited among patients routinely treated at IRCCS Fondazione G.B. Bietti.

Study Design and Procedures

All participants will undergo a baseline visit including:

Medical and ophthalmological history Comprehensive eye examination (visual acuity, tonometry, biomicroscopy, ophthalmoscopy) Non-invasive imaging (e.g., OCT, OCTA) Collection of tears and peripheral blood samples

Patients undergoing therapeutic procedures will also participate in a second visit (within 1-30 days), during which additional biological samples will be collected during routine clinical care, including:

Aqueous humor (via paracentesis) Vitreous humor Subretinal fluid (in RD surgery) Post-injection vitreous reflux (if applicable) All sampling procedures are performed as part of standard clinical or surgical practice and do not introduce additional risk to the patient.

Proteomic Analysis Collected biological matrices (ocular fluids and blood-derived components such as PBMCs and extracellular vesicles) will be analyzed using advanced clinical proteomics techniques. These include high-resolution mass spectrometry (Orbitrap-based platforms) combined with multiplex quantitative approaches (e.g., Tandem Mass Tags).

The study will follow a two-phase approach:

Biomarker discovery phase, aimed at identifying candidate protein biomarkers Validation phase, aimed at confirming their diagnostic and biological relevance Additional targeted analyses (e.g., ELISA) and functional studies (e.g., in vitro cellular models) may be performed to further characterize identified molecular pathways.

Objectives The primary objective is the identification and validation of protein biomarkers associated with AMD, DR, and RD.

Secondary objectives include:

Characterization of molecular mechanisms underlying disease pathogenesis Identification of potential therapeutic targets Investigation of post-translational protein modifications (e.g., phosphoproteomics, ubiquitin-related signatures) Evaluation of surgical variables (e.g., vitreous fragmentation) in biomarker identification

Statistical Analysis Data will be analyzed using appropriate parametric and non-parametric statistical methods. Associations between clinical and molecular variables will be explored, with statistical significance defined as p \< 0.05.

Ethical and Data Management Considerations The study will be conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. All participants will provide written informed consent prior to enrollment. Data will be pseudonymized and handled in compliance with applicable data protection regulations (GDPR)